DVA vs EW: fair value comparison
DaVita Inc. and Edwards Lifesciences Corporation · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, DVA currently sits closer to the top of our discount ranking. EW carries the stronger quality grade.
| DVA | EW | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $181.55 | $84.37 |
| 12-month range | $111.19–$240.09 | $81.26–$90.74 |
| Sector rank | #40 of 113 Healthcare | #45 of 113 Healthcare |
| Quality grade | C | A |
| Leverage | Low | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Oversold |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: DVA fair value analysis · EW fair value analysis